Trisha Suppes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9364829/publications.pdf

Version: 2024-02-01

257450 197818 2,615 63 24 49 h-index citations g-index papers 66 66 66 3111 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Bipolar disorders. Nature Reviews Disease Primers, 2018, 4, 18008.	30.5	518
2	Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry, 2016, 173, 400-407.	7.2	269
3	Early Intervention in Bipolar Disorder. American Journal of Psychiatry, 2018, 175, 411-426.	7.2	218
4	Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectrums, 2020, 25, 502-510.	1.2	178
5	Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Journal of Affective Disorders, 2010, 121, 106-115.	4.1	147
6	Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression. JAMA Psychiatry, 2019, 76, 783.	11.0	135
7	Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. JAMA - Journal of the American Medical Association, 2022, 328, 151.	7.4	55
8	Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. British Journal of Psychiatry, 2019, 214, 27-35.	2.8	54
9	Mixed Depression in Bipolar Disorder: Prevalence Rate and Clinical Correlates During Naturalistic Follow-Up in the Stanley Bipolar Network. American Journal of Psychiatry, 2016, 173, 1015-1023.	7.2	52
10	Toward a Valid Animal Model of Bipolar Disorder: How the Research Domain Criteria Help Bridge the Clinical-Basic Science Divide. Biological Psychiatry, 2016, 79, 62-70.	1.3	52
11	Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11955-11960.	7.1	50
12	Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. Journal of Psychiatric Research, 2016, 78, 86-93.	3.1	48
13	More childhood onset bipolar disorder in the United States than Canada or Europe: Implications for treatment and prevention. Neuroscience and Biobehavioral Reviews, 2017, 74, 204-213.	6.1	48
14	Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. Brain, Behavior, and Immunity, 2020, 88, 631-639.	4.1	44
15	Age of onset of bipolar disorder: Combined effect of childhood adversity and familial loading of psychiatric disorders. Journal of Psychiatric Research, 2016, 81, 63-70.	3.1	41
16	Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression. Cells, 2020, 9, 895.	4.1	36
17	Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RADâ€) project. BMC Psychiatry, 2016, 16, 68.	2.6	33
18	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. World Journal of Biological Psychiatry, 2018, 19, 330-348.	2.6	32

#	Article	IF	CITATIONS
19	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. World Journal of Biological Psychiatry, 2021, 22, 483-494.	2.6	32
20	MAINTENANCE TREATMENT WITH QUETIAPINE WHEN COMBINED WITH EITHER LITHIUM OR DIVALPROEX IN BIPOLAR I DISORDER: ANALYSIS OF TWO LARGE RANDOMIZED, PLACEBO-CONTROLLED TRIALS. Depression and Anxiety, 2013, 30, 1089-1098.	4.1	31
21	First controlled treatment trial of bipolar II hypomania with mixed symptoms: Quetiapine versus placebo. Journal of Affective Disorders, 2013, 150, 37-43.	4.1	28
22	Increased Activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study. American Journal of Psychiatry, 2017, 174, 70-76.	7.2	27
23	The ENGAGE study: Integrating neuroimaging, virtual reality and smartphone sensing to understand self-regulation for managing depression and obesity in a precision medicine model. Behaviour Research and Therapy, 2018, 101, 58-70.	3.1	27
24	Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. Journal of Psychiatric Research, 2021, 133, 82-92.	3.1	27
25	Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. Comprehensive Psychiatry, 2016, 66, 146-156.	3.1	25
26	Testing a clinical staging model for bipolar disorder using longitudinal life chart data. Bipolar Disorders, 2019, 21, 228-234.	1.9	23
27	Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis. Journal of Psychiatric Research, 2017, 88, 38-46.	3.1	21
28	Major depressive disorder with subthreshold hypomania (mixed features): Clinical characteristics of patients entered in a multiregional, placebo-controlled study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 68, 9-14.	4.8	20
29	Obesity and obstetric complications are associated with rapid-cycling in Italian patients with bipolar disorder. Journal of Affective Disorders, 2017, 208, 278-283.	4.1	20
30	The relationship between self-reported borderline personality features and prospective illness course in bipolar disorder. International Journal of Bipolar Disorders, 2017, 5, 31.	2.2	19
31	Peripheral inflammatory biomarkers define biotypes of bipolar depression. Molecular Psychiatry, 2021, 26, 3395-3406.	7.9	19
32	Multigenerational transmission of liability to psychiatric illness in offspring of parents with bipolar disorder. Bipolar Disorders, 2018, 20, 432-440.	1.9	18
33	A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. Journal of Affective Disorders, 2020, 263, 386-395.	4.1	18
34	Predictors of psychosocial outcome of bipolar disorder: data from the Stanley Foundation Bipolar Network. International Journal of Bipolar Disorders, 2019, 7, 28.	2.2	17
35	Online ethics: where will the interface of mental health and the internet lead us?. International Journal of Bipolar Disorders, 2017, 5, 26.	2.2	16
36	A clinical model for identifying an inflammatory phenotype in mood disorders. Journal of Psychiatric Research, 2019, 113, 148-158.	3.1	16

#	Article	IF	Citations
37	More illness in offspring of bipolar patients from the U.S. compared to Europe. Journal of Affective Disorders, 2016, 191, 180-186.	4.1	15
38	Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials. International Journal of Bipolar Disorders, 2017, 5, 36.	2.2	15
39	Double jeopardy in the United States: Early onset bipolar disorder and treatment delay. Psychiatry Research, 2020, 292, 113274.	3.3	15
40	Further Evidence of a Cohort Effect in Bipolar Disorder. Journal of Clinical Psychiatry, 2016, 77, 1043-1049.	2.2	15
41	Corrigendum to "Effectiveness of the Extended Release Formulation of Quetiapine as Monotherapy for the Treatment of Acute Bipolar Depression―[J. Affect. Disord. 121 (1–2) (2010) 106–115]. Journal of Affective Disorders, 2014, 168, 485-493.	4.1	14
42	Age at Onset of Bipolar Disorder Related to Parental and Grandparental Illness Burden. Journal of Clinical Psychiatry, 2016, 77, e1309-e1315.	2.2	13
43	Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania. International Journal of Bipolar Disorders, 2015, 3, 11.	2.2	12
44	Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression. Psychoneuroendocrinology, 2020, 120, 104779.	2.7	11
45	Understanding mechanisms of integrated behavioral therapy for co-occurring obesity and depression in primary care: a mediation analysis in the RAINBOW trial. Translational Behavioral Medicine, $2021, 11, 382-392$.	2.4	11
46	Adding Increased Energy or Activity to Criterion (A) of the DSM-5 Definition of Hypomania and Mania. Journal of Clinical Psychiatry, 2019, 80, .	2.2	11
47	The association between mood state and chronobiological characteristics in bipolar I disorder: a naturalistic, variable cluster analysis-based study. International Journal of Bipolar Disorders, 2018, 6, 5.	2.2	9
48	25 Years of the International Bipolar Collaborative Network (BCN). International Journal of Bipolar Disorders, 2021, 9, 13.	2.2	8
49	Attitudes on pharmacogenetic testing in psychiatric patients with treatmentâ€resistant depression. Depression and Anxiety, 2020, 37, 842-850.	4.1	7
50	Effects of infliximab on brain neurochemistry of adults with bipolar depression. Journal of Affective Disorders, 2021, 281, 61-66.	4.1	7
51	Problem-solving therapy–induced amygdala engagement mediates lifestyle behavior change in obesity with comorbid depression: a randomized proof-of-mechanism trial. American Journal of Clinical Nutrition, 2021, 114, 2060-2073.	4.7	7
52	The Prevalence and Diagnostic Validity of Short-Duration Hypomanic Episodes and Major Depressive Episodes. Current Psychiatry Reports, 2016, 18, 27.	4.5	5
53	Depression With Mixed Features in Major Depressive Disorder: A New Diagnosis or There All Along?. Journal of Clinical Psychiatry, 2018, 79, 94-95.	2.2	5
54	More assortative mating in US compared to European parents and spouses of patients with bipolar disorder: implications for psychiatric illness in the offspring. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 237-245.	3.2	4

TRISHA SUPPES

#	Article	IF	CITATIONS
55	Impact of modification to DSM-5 criterion A for hypomania/mania in newly diagnosed bipolar patients: findings from the prospective BIO study. International Journal of Bipolar Disorders, 2021, 9, 14.	2.2	4
56	Letter to the Editor in response to 2012 article by Frances and Jones. Bipolar Disorders, 2014, 16, 214-215.	1.9	3
57	The factor structure of depressive symptoms in patients with obesity enrolled in the RAINBOW clinical trial. Journal of Affective Disorders, 2021, 281, 367-375.	4.1	2
58	Mania and bipolar depression: complementing not opposing poles—a post-hoc analysis of mixed features in manic and hypomanic episodes. International Journal of Bipolar Disorders, 2021, 9, 36.	2.2	2
59	Chronbiologically-based sub-groups in bipolar I disorder: A latent profile analysis. Journal of Affective Disorders, 2022, 299, 691-697.	4.1	2
60	Illnesses in siblings of US patients with bipolar disorder relate to multigenerational family history and patients severity of illness. Journal of Affective Disorders, 2017, 207, 313-319.	4.1	1
61	Repetitive Transcranial Magnetic Stimulation as a Treatment for Veterans with Cognitive Impairment and Multiple Comorbidities. Journal of Alzheimer's Disease, 2022, 85, 1593-1600.	2.6	1
62	A Brief Commentary on the Bipolar CHOICE Study. Journal of Clinical Psychiatry, 2016, 77, e43-e44.	2.2	0
63	Evidence-Based Treatment Targets, Selection, and Strategies for Acute Manic and Mixed Episodes of Bipolar I Disorder. Journal of Clinical Psychiatry, 2019, 81, .	2.2	O